Reducing triglycerides in REDUCE-IT
Video navigation menu
- Design of the trial 00:49
- Characteristics of study population 03:28
- Outcomes 04:26
- Adverse events and signals 07:16
- More analyses of the REDUCE-IT data 09:04
In the REDUCE-IT trial, treatment with icosapent ethyl resulted in reduction of the individual endpoints:
- A. myocardial infarction, stroke, all-cause death
- B. myocardial infarction, stroke, coronary revascularization
- D. coronary revascularization, bleeding, CV death
- D. stroke, unstable angina, all-cause death
This educational video is part of a series called '4 Things a cardiologist needs to know about triglycerides' that is aimed to guide cardiologists in how triglycerides affect CV risk and how patients with high triglyceride levels can be managed according to recent insights.
Prof. Deepak L. Bhatt, MD, MPH is Executive Director of Interventional Cardiovascular Programs and Professor at Harvard Medical School, Boston, MA, USA.
This educational series is funded by an unrestricted educational grant provided by Amarin.
This is available as accredited online CME for members. Click the button below to enroll:Enroll
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: